Rezatapopt Hits 48% Response Rate in Platinum-Resistant Ovarian Cancer; NDA Set for Q1 2027
PMVP sits 18% above its 52-week low of $1.02.
Summary
The pivotal Phase 2 PYNNACLE primary analysis shows rezatapopt monotherapy produced a 48% confirmed overall response rate (31/65) in platinum-resistant/refractory ovarian cancer, with a 10.4-month median duration of response and an 83% disease control rate. Across all 168 evaluable patients the ORR was 36% with an 8.1-month median DOR, and responses spanned eight tumor types. Safety looks manageable: most treatment-related adverse events were Grade 1 or 2, individual Grade 3 TRAE rates were at or below 7.2%, and 6% of patients discontinued for TRAEs. Management said it expects to submit the NDA for accelerated approval in the first quarter of 2027, which is the next hard milestone. This builds on the August ovarian cancer update that preceded the $50.8 million offering; with $108.5 million in cash as of the Q3 report, the registrational path is funded into early 2027.
At the time of this announcement, PMVP was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.3M. The 52-week trading range was $1.02 to $1.91. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.